Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Leukemia|January 16, 2004
P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylateT Illmer, M Schaich, U Platzbecker, et al.
Blood Cancer Journal|June 14, 2014
Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemiaA Ehninger, M Kramer, C Röllig, et al.
Blood Cancer Journal|August 13, 2016
Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blastsM Cartellieri, A Feldmann, S Koristka, et al.
Blood Cancer Journal|September 19, 2015
Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blastsR Aliperta, M Cartellieri, A Feldmann, et al.
Leukemia|August 21, 2013
Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting systemC Arndt, A Feldmann, M von Bonin, et al.
Bone Marrow Transplantation|September 30, 2008
Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing mediumM von Bonin, F Stölzel, A Goedecke, et al.
Annals of Hematology|May 6, 2004
Imatinib mesylate selectively influences the cellular metabolism of cytarabine in BCR/ABL negative leukemia cell lines and normal CD34+ progenitor cellsM Bornhäuser, T Illmer, P Le Coutre, et al.
Bone Marrow Transplantation|January 12, 2016
Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantationC S Link, R Teipel, F Heidenreich, et al.
Leukemia|May 16, 2015
NFATc1 as a therapeutic target in FLT3-ITD-positive AMLS K Metzelder, C Michel, M von Bonin, et al.
Leukemia|August 19, 2015
Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trialJ M Middeke, R Herbst, S Parmentier, et al.
Pageof 1